Citations

Clear

14 citation(s) found for "Scott, Gregory".

Telomere length as a marker of biological age in paediatric multiple sclerosis
Jacques, Kayla , Race, Jonathan , Goyne, Christopher, Fair, Ashley, Schuette, Allison, Yang, Jennifer H. , Caillier, Stacy J. , Aaen, Gregory Scott, Abrams, Aaron , Benson, Leslie, Casper, T Charles, Chitnis, Tanuja, Gorman, Mark , Lotze, Tim, Mar, Soe , Ness, Jayne , Rose, John W. , Schreiner, Teri , Tillema, Jan-Mendelt , Waldman, Amy T, Wheeler, Yolanda , Oksenberg, Jorge, Lin, Jue , Waubant, Emmanuelle, Aaen, Gregory S , Krupp, Lauren , Wheeler, Yolanda S , Yang, Jennifer H , Aaen, Gregory , Benson, Leslie , Casper, T. Charles , Chitnis, Tanuja , Rensel, Mary R. , Rodriguez, Moses , Schreiner, Teri , Tillema, Jan‐Mendelt , Waldman, Amy , Oksenberg, Jorge R. , Waubant, Emmanuelle L. , Graves, Jennifer

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | February 17, 2026 | Volume: 97 | Issue: 4 | Pages: 302-308

10.1136/jnnp-2025-336736 | PMID 41500800 Get It

Background Increased chronological age correlates with reduced relapse rates and increased disability in multiple sclerosis (MS). Biological age may better capture ageing’s impact on MS and might accelerate due to MS itself. Establishing accelerated biological ageing in adults is complicated by normal ageing and comorbidities. Telomere length, a well-recognised biological ageing marker, is shortened in adults with MS and associated with disability. Demonstrating accelerated biological ageing in paediatric-onset MS (POMS) would strengthen the hypothesis that MS drives premature biological ageing. This study aimed to determine if telomere length differs in POMS compared to age-similar healthy controls. Methods We performed a cross-sectional case-control study of whole blood samples and clinical data from The US Network of Pediatric MS Centers. Real-time quantitative PCR measured telomere length, expressed as a telomere to somatic DNA ratio (T/S ratio). T/S ratio was compared between cases and age-similar healthy controls using multivariate regression analysis adjusting for chronological age, sex, race, ethnicity, tobacco exposure, socioeconomic status and body mass index. Results We analysed 300 POMS cases and 200 controls. The unadjusted mean T/S ratios were 1.66 (SD 0.32) for cases and 1.71 (SD 0.29) for controls (mean difference –0.05, 95% CI –0.10 to 0.01, p=0.08). After adjusting for key covariables with face validity, POMS participants had a mean 0.086 shorter T/S ratio than controls (95% CI 0.015 to 0.157, p=0.018). Conclusions POMS participants demonstrated shorter telomeres than age-similar controls in a multivariable model adjusting for sociodemographic variables, suggesting that MS may contribute to accelerated biological ageing.
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer
Lee, W. Robert , Dignam, James J., Amin, Mahul B. , Bruner, Deborah Watkins , Low, Daniel A. , Shah, Amit B. , D’Souza, David , Michalski, Jeff M. , Dayes, Ian S. , Seaward, Samantha A. , Hall, William A. , Nguyen, Paul L. , Pisansky, Thomas M. , Faria, Sergio , Chen, Yuhchyau , Rodgers, Joseph P., Bruner, Deborah , Swanson, Gregory P , Michalski, Jeff M , Dayes, Ian S , Seaward, Samantha A , Hall, William A , Sandler, Howard M , Swanson, Gregory P. , Sandler, Howard M.

Mayo Clinic

Journal of Clinical Oncology | May 17, 2024 | Volume: 42 | Issue: 20 | Pages: 2377-2381

10.1200/jco.23.02445 | PMID 38759121 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. NRG Oncology RTOG 0415 is a randomized phase III noninferiority (NI) clinical trial comparing conventional fractionation (73.8 Gy in 41 fractions) radiotherapy (C-RT) with hypofractionation (H-RT; 70 Gy in 28) in patients with low-risk prostate cancer. The study included 1,092 protocol-eligible patients initially reported in 2016 with a median follow-up of 5.8 years. Updated results with median follow-up of 12.8 years are now presented. The estimated 12-year disease-free survival (DFS) is 56.1% (95% CI, 51.5 to 60.5) for C-RT and 61.8% (95% CI, 57.2 to 66.0) for H-RT. The DFS hazard ratio (H-RT/C-RT) is 0.85 (95% CI, 0.71 to 1.03), confirming NI ( P < .001). Twelve-year cumulative incidence of biochemical failure (BF) was 17.0% (95% CI, 13.8 to 20.5) for C-RT and 9.9% (95% CI, 7.5 to 12.6) for H-RT. The HR (H-RT/C-RT) comparing biochemical recurrence between the two arms was 0.55 (95% CI, 0.39 to 0.78). Late grade ≥3 GI adverse event (AE) incidence is 3.2% (C-RT) versus 4.4% (H-RT), with relative risk (RR) for H-RT versus C-RT 1.39 (95% CI, 0.75 to 2.55). Late grade ≥3 genitourinary (GU) AE incidence is 3.4% (C-RT) versus 4.2% (H-RT), RR 1.26 (95% CI, 0.69 to 2.30). Long-term DFS is noninferior with H-RT compared with C-RT. BF is less with H-RT. No significant differences in late grade ≥3 GI/GU AEs were observed between assignments (ClinicalTrials.gov identifier: NCT00331773 ).
Skin histopathology, including a significant itch response, associated chemically-induced contact hypersensitivity reactions in the mouse are, in part, a consequence of skin infiltrating eosinophils (163.16)
Condjella, Rachel, Protheroe, Cheryl, Ochkur, Sergei I. , Zellner, Katie R. , Colbert, Dana, Scott, Gregory, Jacoby, David B. , Fryer, A.D. , Lee, Nancy , Lee, James

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 186 | Issue: 1_Supplement | Pages: 163.16-163.16

10.4049/jimmunol.186.supp.163.16 Get It

Abstract Atopic dermatitis and allergic contact dermatitis are two of the most common skin diseases. In both diseases, eosinophils have been suggested as potential contributors of the pathologies linked with these skin conditions. Our goal was to establish a causative relationship between the inflammatory response of chemically induced contact hypersensitivity and eosinophil-mediated activities. Wild type and eosinophil-less PHIL mice were sensitized and challenged with 2,4-dinitrochlorobenzene (DNFB) or alternatively trimellitic anhydride (TMA). Time lapsed videography was used to capture the number of itching events associated with treatment. Immunohistochemistry for eosinophils and nerves was performed to correlate the effect of dermatitis on innervation and eosinophil accumulation in these mice. Our studies showed that in both the DNFB and TMA models a robust eosinophil infiltrate occurred that was accompanied by copious levels of eosinophil degranulation. More importantly, these studies demonstrated that metrics of inflammation (e.g., induced ear swelling (i.e., thickness)) was reduced in PHIL mice relative to wild type. Our observations were also directly correlative with a loss of nerve growth and branching in PHIL mice. These data implicate eosinophils as contributors to the pathologies linked with chemically-induced contact hypersensitivity, including the induced itch responses associated with these models.
Eosinophils increase airway sensory nerve density in mice and in human asthma
Drake, Matthew G. , Scott, Gregory D. , Blum, Emily , Lebold, Katie M. , Lee, James J. , Fryer, A.D. , Costello, Richard W. , Jacoby, David B. , Blum, Emily D , Lebold, Katherine M , Fryer, Allison D , Costello, Richard W , Jacoby, David B , Nie, Zhenying , Drake, Matthew G

Mayo Clinic

Science Translational Medicine | September 5, 2018 | Volume: 10 | Issue: 457 | Pages: No page available

10.1126/scitranslmed.aar8477 | PMID 30185653 Get It

Eosinophils increase airway sensory nerve density in humans with asthma and in mice, which promotes airway hyperresponsiveness.
NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer.
Lee, W. Robert , Dignam, James J., Amin, Mahul B. , Low, Daniel J. , Shah, Amit B. , D’Souza, David , Michalski, Jeff M. , Dayes, Ian S. , Seaward, Samantha A. , Hall, William A. , Pisansky, Thomas M. , Faria, Sergio , Chen, Yuhchyau , Bruner, Deborah Watkins , Swanson, Gregory P. , Seaward, Samantha A , Nguyen, Paul L. , Koontz, Bridget F. , Paulus, Rebecca , Sandler, Howard M. , Dayes, Ian S

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 34 | Issue: 2_suppl | Pages: 1-1

10.1200/jco.2016.34.2_suppl.1 Get It

1 Background: To determine whether the efficacy of a hypofractionated (H) schedule is no worse than a conventional (C) schedule in men with low-risk prostate cancer. Methods: From April 2006 to December 2009, one thousand one hundred fifteen men with low-risk prostate cancer (clinical stage T1-2a, Gleason ≤ 6, PSA < 10) were randomly assigned 1:1 to a conventional (C) schedule (73.8 Gy in 41 fractions over 8.2 weeks) or to a hypofractionated (H) schedule (70 Gy in 28 fractions over 5.6 weeks). The trial was designed to establish with 90% power and alpha = 0.05 that (H) results in 5-year disease-free survival (DFS) that is not lower than (C) by more than 7% (hazard ratio (HR) < 1.52). Secondary endpoints include freedom from biochemical recurrence (FFBR) and overall survival. At the third planned interim analysis (July 2015), the NRG Oncology Data Monitoring Committee recommended that the results of the trial be reported. Results: One thousand one hundred and one protocol eligible men were randomized: 547 to C and 554 to H. Median follow-up is 5.9 years. Baseline characteristics are not different according to treatment arm. At the time of analysis 185 DFS events have been observed; 99 in the C arm and 86 in the H arm. The estimated 7-year disease-free survival is 75.6% (95% CI 70.3, 80.1) in the C arm and 81.8% (77.5, 85.3) in the H arm. The DFS HR (C/H) is 0.85 (0.64, 1.14). Comparison of biochemical recurrence (HR = 0.77, (0.51, 1.17)) and overall survival (HR = 0.95, (0.65, 1.41)) also met protocol non-inferiority criteria. Grade ≥ 3 GI toxicity is 3.0% (C) vs. 4.6% (H), Relative risk (RR) for H vs. C 1.53, (95% CI 0.86, 2.83); grade ≥ 3 GU toxicity is 4.5% (C) vs. 6.4% (H), RR = 1.43 (0.86,2.37). Conclusions: In men with low-risk prostate cancer, 70 Gy in 28 fractions over 5.6 weeks is non-inferior to 73.8 Gy in 41 fractions over 8.2 weeks. Clinical trial information: NCT00331773.
Human and Mouse Eosinophils Have Antiviral Activity against Parainfluenza Virus
Drake, Matthew G. , Bivins-Smith, Elizabeth R., Proskocil, Becky J. , Scott, Gregory D. , Lee, James J. , Lee, Nancy A., Fryer, A.D. , Nie, Zhenying , Jacoby, David B. , Fryer, Allison D , Drake, Matthew G

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | April 6, 2016 | Volume: 55 | Issue: 3 | Pages: 387-394

10.1165/rcmb.2015-0405oc | PMID 27049514 Get It

Abstract Respiratory viruses cause asthma exacerbations. Because eosinophils are the prominent leukocytes in the airways of 60–70% of patients with asthma, we evaluated the effects of eosinophils on a common respiratory virus, parainfluenza 1, in the lung. Eosinophils recruited to the airways of wild-type mice after ovalbumin sensitization and challenge significantly decreased parainfluenza virus RNA in the lungs 4 days after infection compared with nonsensitized animals. This antiviral effect was also seen in IL-5 transgenic mice with an abundance of airway eosinophils (NJ.1726) but was lost in transgenic eosinophil-deficient mice (PHIL) and in IL-5 transgenic mice crossed with eosinophil-deficient mice (NJ.1726-PHIL). Loss of the eosinophil granule protein eosinophil peroxidase, using eosinophil peroxidase–deficient transgenic mice, did not reduce eosinophils’ antiviral effect. Eosinophil antiviral mechanisms were also explored in vitro. Isolated human eosinophils significantly reduced parainfluenza virus titers. This effect did not involve degradation of viral RNA by eosinophil granule RNases. However, eosinophils treated with a nitric oxide synthase inhibitor lost their antiviral activity, suggesting eosinophils attenuate viral infectivity through production of nitric oxide. Consequently, eosinophil nitric oxide production was measured with an intracellular fluorescent probe. Eosinophils produced nitric oxide in response to virus and to a synthetic agonist of the virus-sensing innate immune receptor, Toll-like receptor (TLR) 7. IFNγ increased expression of eosinophil TLR7 and potentiated TLR7-induced nitric oxide production. These results suggest that eosinophils promote viral clearance in the lung and contribute to innate immune responses against respiratory virus infections in humans.
SCAI/ACC/AHA Expert Consensus Document
Dehmer, Gregory , Blankenship, James C. , Dwyer, James G., Feldman, Dmitriy N. , Gardner, Timothy J., Singh, Mandeep, Çilingiroğlu, Mehmet , Grines, Cindy L.

Mayo Clinic

Catheterization and Cardiovascular Interventions | July 16, 2014 | Volume: 84 | Issue: 2 | Pages: 169-187

10.1002/ccd.25371 | PMID 25045090 Get It

SCAI/ACC/AHA Expert Consensus Document: 2014 Update on Percutaneous Coronary Intervention Without On-Site Surgical Backup
Dehmer, Gregory , Blankenship, James C. , Dwyer, James G., Feldman, Dmitriy N. , Gardner, Timothy J., Çilingiroğlu, Mehmet , Grines, Cindy L. , Singh, Mandeep

Mayo Clinic

Circulation | March 18, 2014 | Volume: 129 | Issue: 24 | Pages: 2610-2626

10.1161/cir.0000000000000037 | PMID 24637561 Get It